Richard L Keenan, Age 531241 Morristown Dr, Toms River, NJ 08753

6403578, Jun 11, 2002

Aug 4, 1995

08/464779

William Edward Bondinell - Wayne PA
James Francis Callahan - Philadelphia PA
William Francis Huffman - Malvern PA
Richard McCulloch Keenan - Malvern PA
Thomas Wen-Fu Ku - Dresher PA
Kenneth Allen Newlander - West Chester PA
James Martin Samanen - Phoenixville PA
Irene Nijole Uzinskas - Villanova PA

SmithKline Beecham Corporation - Philadelphia PA

A61K 3155

514221, 514215, 514213, 540490, 540500, 540506, 540512, 540513, 540504, 540514, 540523

This invention relates to compounds of the formulae: wherein A is O, S, NâR or CHR ; A is NâR or CHR ; R is a sidechain containing an acid or ester group; R , R and R are substituents such as H, alkyl and aryl alkyl, and R is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.

6825188, Nov 30, 2004

Oct 22, 2003

10/691241

James Francis Callahan - Philadelphia PA
Russell Donovan Cousins - Oxford PA
Richard McCulloch Keenan - Malvern PA
Chet Kwon - King of Prussia PA
William Henry Miller - Schwenksville PA
Irene Nijole Uzinskas - Villanova PA

SmithKline Beecham Corporation - Philadelphia PA

A61K 3144

51421207, 540531

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.

2001003, Oct 25, 2001

Jan 24, 2001

09/769125

Fadia Ali - Cherry Hill NJ, US
William Bondinell - Wayne PA, US
Richard Keenan - Malvern PA, US
Thomas Ku - Dresher PA, US
William Miller - Schwenksville PA, US
James Samanen - Phoenixville PA, US

SmithKline Beecham Corporation

C07D241/20
C07D239/12

544/326000, 544/330000, 544/336000

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis.

2003012, Jul 3, 2003

Dec 16, 2002

10/320084

James Callahan - Philadelphia PA, US
Russell Cousins - Oxford PA, US
Richard Keenan - Malvern PA, US
Chet Kwon - King of Prussia PA, US
William Miller - Schwenksville PA, US
Irene Uzinskas - Villanova PA, US

SmithKline Beecham Corporation

A61K031/55
C 07D 4 3/02

514/212070, 540/523000

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.

2004023, Nov 25, 2004

May 18, 2004

10/848309

Donna Tran - Trevose PA, US
Richard Keenan - Schaumburg IL, US

B32B031/00

428/195100, 156/277000, 264/509000, 156/196000

A heat shrink sleeve label, when applied to a container, glass or plastic, replicates the look and feel of etched glass or frosted glass through a combination of an upper coating and a lower coating on a shrink film. The shrink film may be polyvinyl chloride, polyethylene terephthalate with or without glycol, or oriented poly styrene. Both water and solvent base frost inks are applied to the outer surface of the film. Frost inks contain a combination of pigments, waxes and solvents to achieve the frosted/acid etched look and feel. A tint coating is applied to the inner surface of the film. To prevent a “wet” look when the shrink sleeve label is not printed with a tint coating, an anti-wet coating is printed on the inner surface of the film to eliminate the spotty and/or water stain appearance when applied to a container that contains imperfections.

5234917, Aug 10, 1993

Nov 30, 1990

7/621491

Joseph A. Finkelstein - Philadelphia PA
Judith Hempel - Philadelphia PA
Richard M. Keenan - Philadelphia PA
James Samanen - Philadelphia PA
Joseph Weinstock - Philadelphia PA

A61K 31675
C07D23354
C07D27704
C07D27730
C07D24904
C07D26334
C07D26104
C07F 906

514397

Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

5418250, May 23, 1995

Jun 14, 1993

8/076609

Joseph A. Finkelstein - Philadelphia PA
Richard M. Keenan - Malvern PA
Joseph Weinstock - Phoenixville PA

SmithKline Beecham Corporation - Philadelphia PA

A61K 31415
C07D23366
C07D40906

514397

Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

6159964, Dec 12, 2000

Jul 27, 1999

9/091937

Fadia E. Ali - Cherry Hill NJ
William E. Bondinell - Wayne PA
Richard M. Keenan - Malvern PA
Thomas Wen-Fu Ku - Dresher PA
William H. Miller - Schwenksville PA
James Samanen - Phoenixville PA

SmithKline Beecham Corporation - Philadelphia PA

A61K 315513
A61P 702
C07D40112

514221

Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form --(CHR. sup. g). sub. a --U--(CHR. sup. g). sub. b --V--; Q. sup. 1, Q. sup. 2, Q. sup. 3 and Q. sup. 4 are independently N or C--R. sup. y, provided that no more than one Q. sup. 1, Q. sup. 2, Q. sup. 3 and Q. sup. 4 is N; R' is H or C. sub. 1-6 alkyl, C. sub. 3-7 cycloalkyl-C. sub. 0-6 -alkyl or Ar--C. sub. 0-6 alkyl; R. sup. g is H or C. sub. 1-6 alkyl, Het-C. sub. 0-6 alkyl, C. sub. 3-7 cycloalkyl-C. sub. 0-6 alkyl or Ar--C. sub. 0-6 alkyl; R. sup. k is R. sup. g, --C(O)R. sup. g or --C(O)OR. sup. g R. sup. i is H, C. sub. 1-6 alkyl, Het-C. sub. 0-6 alkyl, C. sub. 3-7 cycloalkyl-C. sub. 0-6 alkyl, Ar--C. sub.